Metabolites of a G protein-coupled receptor modulator containing 1,2,4-oxadiazole and piperazine substructures were identified in vitro in human, rat, and dog hepatocyte incubates and in vivo in rat plasma, bile, urine, and feces by using 14 C-radiolabeled parent compound. Exposure coverage for the major circulating metabolites in humans at steady state and in preclinical species used in drug safety assessments was determined by using pooled plasma samples collected from a human multiple ascending dose study and a 3-month rat toxicokinetic study. Metabolites M1 and M2, which were formed by opening of the 1,2,4-oxadiazole ring, were observed as major metabolites both in vitro and in vivo across species. The carboxylic acid metabolite M2 was presumably formed through reductive N-O bond cleavage of the oxadiazole ring and subsequent hydrolysis. However, the mechanism for the formation of the unusual N-cyanoamide metabolite M1 remains uncertain. Neither M1 nor M2 had any target activity, as did parent drug P. In rat bile, rearranged Cys-piperazine and Gly-Cys-piperazine adducts, involving the formation of a five-membered heteroaromatic imidazole derivative from a six-membered piperazine ring, were observed as minor metabolites. These findings support a previously reported mechanism regarding glutathione detoxification for piperazine bioactivation products.
Introduction
Compound P (Fig. 1) is a G protein-coupled receptor modulator in development that is intended for central nervous system indications. It has the molecular weight of 487 and contains a 3-(piperazin-1-ylmethyl)-1,2,4-oxadiazole substructure connected to a substituted aromatic (Ar) group (Fig. 1) . The Ar group is not disclosed for proprietary reasons and would appear more lipophilic than the disclosed region. However, almost all of the biotransformation of compound P occurred in either the oxadiazole or piperazine ring region.
Metabolism involving 1,2,4-oxadiazole ring-opening has been of interest in the literature (Lan et al., 1973; Gyarmati et al., 1976; Yabuki et al., 1993; Dalvie et al., 2002; Allan et al., 2006; Bateman et al., 2006; Tsalta et al., 2011) . The oxadiazole ring can undergo NADPH-dependent reductive cleavage of the N-O bond and then subsequent hydrolysis, to produce various ring-opened products such as amides and carboxylic acids (Scheme 1a) (Lan et al., 1973; Gyarmati et al., 1976; Allan et al., 2006; Tsalta et al., 2011) . It is worth noting that the reductive N-O bond cleavage for the oxadiazole could also occur chemically, e.g., through reaction with ferrous hydroxide (Lan et al., 1973) . Reductive N-O cleavage is also common to the biotransformation of isoxazole, another fivemembered heteroaromatic ring with a N-O bond (Dalvie et al., 2002; Zhang et al., 2008a) . However, there would be no hydrolysis steps after reductive cleavage of the N-O bond of the isoxazole, compared with the oxadiazole (Scheme 1a). A ring-opened Ncyanoamide metabolite produced from a 3,5-substituted 1,2,4-oxadiazole ring, as illustrated in Scheme 1b, is a very unusual ring-opened product and was first reported as a major rat biliary metabolite of the calcium channel antagonist methyl 5-(3-((benzyl(methyl)amino)methyl)-1,2,4-oxadiazol-5-yl)-2,6-dimethyl-4-(3-nitrophenyl)-1,4-dihydropyridine-3-carboxylate (SM-6586) (Yabuki et al., 1993) . A similar metabolite was found as a minor metabolite of a phosphodiesterase 4 inhibitor in liver microsomes of several species (Bateman et al., 2006) . In both reports, the unusual Ncyanoamide metabolites were characterized with 1 H-NMR. Yabuki et al. (1993) verified their findings by using a synthesized standard. The mechanism for the formation of N-cyanoamide is still unknown. A review article suggested that the formation of an Ncyanoamide from SM-6586 might be initiated through oxidation instead of reduction, e.g., hypothesized hydroxylation at the saturated carbon in 3-substitution of the oxadiazole derivative (Dalvie et al., 2002) .
Two ring-opened products of 1,2,4-oxadiazole, i.e., a carboxylic acid metabolite and a N-cyanoamide metabolite, were observed as major metabolites of compound P in vitro and in vivo, particularly in plasma samples from humans and from preclinical species used in drug safety assessments. Understanding the level of metabolite exposure during safety testing has been considered by regulatory authorities to be one of the critical drug metabolism issues in modern drug development (Food and Drug Administration, 2008; Baillie, 2009; Ma et al., 2010; Ramanathan et al., 2010; Nedderman et al., 2011) . The guidance on safety testing of drug metabolites published by the Food and Drug Administration in 2008 recommends that the safety assessment of major drug metabolites be completed before large-scale clinical trials are initiated (Food and Drug Administration, 2008) . In the present study, the exposure coverage for major circulating human metabolites of compound P was determined by using pooled residual plasma samples collected from a human multiple ascending dose (MAD) study versus 3-month rat toxicokinetic (TK) studies.
Materials and Methods
Materials. Cryopreserved human hepatocytes were purchased from CellzDirect (Durham, NC) (lots Hu777 and Hu778; both white male). The cells underwent thawing, washing, and resuspension before incubation. The viability of the human hepatocytes after thawing was 69% and 75% for lots Hu777 and Hu778, respectively. Wistar Han rat hepatocytes were freshly prepared in Veterinary Medicine, AstraZeneca (Wilmington, DE). The rat hepatocyte viability was 95%. Cryopreserved male Beagle dog hepatocytes were purchased from CellzDirect. The cells underwent thawing, washing, and resuspension before incubation. The viabilities of dog hepatocytes after thawing were determined to be 95%. Pooled human liver microsomes, cytosol, and S9 fractions were supplied by BD Gentest (Woburn, MA). Human cDNA-expressed P450 enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) and FMO enzymes (FMO1, FMO2, and FMO3) were made by BD Gentest, from insect cells infected with recombinant baculovirus containing a cDNA insert for individual human P450 and FMO enzymes. All human P450 enzymes were coexpressed with human P450 reductase, and some were coexpressed with cytochrome b 5 .
FIG. 1. Compound P, containing 1,2,4-oxadiazole and piperazine substructures. SCHEME 1. Two types of 1,2,4-ozadiazole ring opening, i.e., reductive cleavage of the N-O bond (a) and unknown cleavage leading to the formation of an unusual N-cyanoamide metabolite (b).
Enzyme redox cofactors NADPH, NADP, NADH, and NAD, aldehyde oxidase (AO) reduction cofactors 2-hydroxpyrimidine, 1-methylnicotinamide, and benzaldehyde, xanthine oxidase reduction cofactor xanthine, P450 inhibitor 1-aminobenzotriazole (ABT), FMO inhibitor methimazole, and AO oxidation positive control substrate phthalazine were obtained from SigmaAldrich (St. Louis, MO). The NADPH-regenerating system was acquired from BD Biosciences (San Jose, CA).
Synthesis of N-Cyanoamide Metabolite 1. The synthetic route is depicted in Scheme 2. A solution of 0.21 mmol of acid 2, 0.16 ml (1.2 mmol) of triethylamine, and 102 mg (0.32 mmol) of O- (benzotriazol-1-yl) -N,N,NЈ,NЈ-tetramethyluronium tetrafluoroborate in 1.5 ml of DMF was degassed with N 2 for 1 min, and 162 mg (3.85 mmol) of cyanamide was added. The solution was stirred for 1 h and was then added to 10 ml of 1 M HCl. The solution was extracted three times with 10 ml of CHCl 3 . The combined organic phases were concentrated to dryness and purified with reverse-phase HPLC [18 to 35% acetonitrile (MeCN)/0.1 M aqueous NH 4 HCO 3 (pH 10) over 10 min; 30-ϫ 100-mm Gemini NX C18 column; Phenomenex, Torrance, CA], to yield 0.2 mmol of N-cyanoamide 1 as a yellow solid. The compound was characterized by using high-resolution LC-MS and various NMR techniques.
Route of Synthesis of [ 14 C]P. The route of radiolabel synthesis is depicted in Scheme 3.
Synthesis of nitrile 4. A degassed solution of 1.17 mmol of aryl bromide 3, 55 mg (52 mCi, 0.47 mmol) of Zn( 14 CN) 2 , and 108 mg (0.093 mmol) of Pd(PPh 3 ) 4 in 1.1 ml of DMF was stirred and heated at 120°C for 16 h. The solvent was removed under reduced pressure, and the residue was purified through silica gel chromatography (20% ethyl acetate/hexanes). The combined product-containing fractions were concentrated to dryness to yield 51 mCi of nitrile 4 (87% radiochemical purity).
Synthesis of acid [ 14 C]2. A solution of 47 mCi (0.88 mmol) of nitrile 4 in 1.9 ml of methanol was stirred as 177 mg (4.44 mmol) of NaOH in 0.75 ml of water was added slowly. The solution was heated at 75°C for 16 h and, after cooling to room temperature, the methanol was removed. The crude reaction slurry was then diluted with 5 ml of 1 M HCl and was stirred for 3 h at room temperature. The solvent was removed with a pipette, and the residue was washed five times with 2 ml of 1 N HCl. The solid was crushed and rinsed four times with 5 ml of water to yield 30 mCi of [ 14 C]2 as a yellow solid (93% radiochemical purity). The combined water washes were acidified to yield an additional 11 mCi as a yellow precipitant (94% radiochemical purity).
Synthesis of amide 5. A slurry of 30 mCi (0.56 mmol) of acid [ 14 C]2 in 2 ml of CH 2 Cl 2 was stirred as 0.15 ml (1.68 mmol) of oxalyl chloride and 5 l of DMF were added. After 2 h, the solvent was removed and the residue was taken up in 2 ml of MeCN and was added to a slurry of 217 mg (0.84 mmol) of (Z)-tert-butyl-4-[2-amino-2-(hydroxyimino)ethyl]piperazine-1-carboxylate and 170 mg of K 2 CO 3 in 4 ml of MeCN. After overnight stirring, the reaction mixture was diluted with 20 ml of water, and the solids were removed through filtration and rinsed with 20 ml of water. The solids were then dissolved in 25 ml of CHCl 3 , and the resulting solution was extracted twice with 10 ml of water and then dried (Na 2 SO 4 ). Filtration followed by concentration afforded 28 mCi of 5 with a radiochemical purity of 83%.
Synthesis of oxadiazole 6. A solution of 23 mCi (0.42 mmol) of piperazine 5 in 7 ml of tetrahydrofuran was stirred under a vigorous flow of N 2 as 0.6 ml of a 1 M solution of tetrabutylammonium fluoride in tetrahydrofuran was added dropwise. After complete addition, the solution was stirred overnight. The solvent was then removed, and the residue was dissolved in 50 ml of ethyl acetate. The organic layer was washed with 20 ml of saturated aqueous NaCl, and the organic layer was then dried over Na 2 SO 4 . After removal of the drying agent, the solution was concentrated to dryness and the residue was dissolved in 4 ml of 80% MeCN/0.1% aqueous TFA and was subjected to preparative HPLC [40 to 50% MeCN/0.1% TFA over 20 min; 21.2-ϫ 250-mm Phenomenex Luna C18(2) column]. The combined product-containing fractions were extracted four times with ethyl acetate. The combined organic layers were dried with Na 2 SO 4 and filtered, and the resulting solution was concentrated to dryness to yield 17 mCi of 6 as a yellow oil (98% radiochemical purity).
Synthesis of [ 14 C]P.
A solution of 4.0 mCi (0.068 mmol) of di-tert-butyl dicarbonate amide 6 in 200 l of CH 2 Cl 2 was stirred at room temperature as 100 l of TFA was added, and the resulting solution was stirred for 2 h. The solution was concentrated to dryness, and the residue was taken up in 2.5 ml of 80% aqueous MeCN. The resulting solution was subjected to preparative HPLC [20 to 50% MeCN/0.1% TFA over 20 min; 21.2-ϫ 250-mm Phenomenex Luna C18(2) column], and the product-containing fractions were combined and concentrated to remove the MeCN. The solution was then passed through a 100-mg Oasis HLB SepPak cartridge (Waters, Milford, MA), which was eluted with ethanol to yield 2 mCi of [ 14 C]P with a radiochemical purity of Ͼ99.5% and a specific activity of 58.5 mCi/mmol. 1 H-NMR, LC-MS, and coelution of the product on two orthogonal HPLC columns confirmed the identity of [ 14 C]P. Hepatocyte Incubations. [ 14 C]P was incubated at a nominal initial concentration of 10 M in human, rat, and dog hepatocytes, at 2 ϫ 10 6 viable cells per ml. The specific activity of [ 14 C]P was approximately 30 Ci/mol, which was prepared by mixing labeled and unlabeled P at an approximately equimolar ratio for automatic metabolite identification in LC-MS by using the 14 C/ 12 C isotope ratio. The hepatocyte incubations were performed at 37°C for 2 h in Williams E medium containing 2 mM glutamine, supplemental ITSϩ mixture (consisting of insulin, transferrin, and selenium), and 25 mM HEPES. After 120 min of incubation, 2 volumes of MeCN were added to terminate metabolic reactions. The solvent in aliquots of supernatants of hepatocyte incubates was evaporated at 25°C by using a centrifugal vacuum evaporator. The dry residues were reconstituted with 95% water/5% MeCN containing 0.05% formic acid, and then aliquots of reconstituted samples were injected into the LC system for metabolite profiling and identification. Aliquots of representative supernatant samples were also analyzed, to ensure that there were no artifacts from the drying and reconstitution process.
Chemical Inhibition of P450 Activity in Human and Rat Hepatocytes. Compound P (10 M) was incubated at 37°C with human or rat hepatocytes at 2 ϫ 10 6 cells per ml, in the presence or absence of 1 mM ABT. ABT was preincubated with hepatocytes for 30 min, to increase its inhibitory effect on the P450 enzymes. The reactions were started with the addition of compound P and were stopped with the addition of 2 volumes of MeCN after 60 min of incubation.
Human Liver S9 Fraction Incubations. Compound P (10 M) or M1 authentic standard (10 M) was incubated with human liver S9 fraction (1 mg/ml protein) in triplicate at 37°C. Incubation mixtures contained 0.1 M potassium phosphate buffer (pH 7.4), 5 mM MgCl 2 , and 1 mM concentrations of various cofactors (NADPH-regenerating system, NADH, NAD, NADP, AO reduction cofactors 2-hydroxypyrimidine and 1-methylnicotinamide, and xanthine oxidase reduction cofactor xanthine). The incubations were terminated at 120 min with the addition of 1 volume of MeCN containing 0.1 M hydroxytriazolam and 4-hydroxydiclofenac as internal standards for positive or negative electrospray-ionization LC-MS/MS quantitative analysis. Negative controls in the absence of cofactors were included in the experiment. Compound P was also incubated in the buffer without S9, to evaluate its chemical stability under the incubation conditions. The positive control compound phthalazine was incubated at 2 M substrate concentration, to verify the AO activity in liver fractions (Obach et al., 2004) .
Anaerobic Incubations with Human S9 Fractions. It was reported that the AO-catalyzed reduction reactions take place under anaerobic conditions . Therefore, the incubation mixtures were bubbled with nitrogen gas for 20 s on ice before the addition of cofactors to initiate the reactions. Compound P (10 M) was incubated with human liver S9 fraction (1 mg/ml protein) in triplicate at 37°C. Incubation mixtures also contained 0.1 M potassium phosphate buffer (pH 7.4), 5 mM MgCl 2 , and 1 mM concentrations of various AO reduction cofactors, i.e., 2-hydroxypyrimidine, 1-methylnicotinamide, and benzaldehyde . The reactions were terminated after 30 min as described above.
Human Liver Microsomal and Cytosolic Incubations. Compound P (10 M) was incubated with pooled human liver microsomes (1 mg/ml protein) or cytosol (1 mg/ml protein) in triplicate at 37°C. Incubation mixtures also contained 0.1 M potassium phosphate (pH 7.4), 5 mM MgCl 2 , and 1 mM redox cofactor (NADPH, NADP, NADH, or NAD). Negative controls in the absence of cofactors were included in the experiment. Reactions were terminated at 60 min as described above.
Incubations with Human cDNA-Expressed P450 or FMO Enzymes. Compound P (1 M) was incubated with human P450 enzymes (CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, and CYP3A5) at 50 pmol/ml protein or FMO enzymes (FMO1, FMO2, and FMO3) at 250 g/ml in triplicate at 37°C. Incubation mixtures also contained 0.1 M potassium phosphate buffer (pH 7.4), 5 mM MgCl 2 , and a NADPH-regenerating 14 C]P (incorporating 3.7 MBq/kg) to male and female Han Wistar rats, were pooled to yield a representative sample for each sex and each sample matrix in the present study. Plasma samples collected at different time points within the 24-h period after dosing were pooled in a commonly used "time-interval proportional" fashion Hop et al., 1998) , so that the pooled sample represented the mean concentration (or AUC) of the time period. Bile, urine, or fecal homogenate samples were pooled in proportion to originally collected sample weights in the rat mass balance study, so that the pooled sample represented the cumulative excretion through each route. Aliquots of pooled plasma, bile, or urine samples were mixed with 2 volumes of MeCN to precipitate proteins. The solvent in the supernatants was reduced under vacuum at 30°C by using a centrifugal vacuum evaporator. The residues were reconstituted in approximately one fifth of the original sample volumes. Aliquots of 5 g of pooled fecal homogenates were extracted with three portions of 5 ml of 90:10 (v/v) MeCN/water. The combined extracts were reduced to less than 1 ml under vacuum at 30°C and then were reconstituted to approximately 1.5 ml with the addition of water/methanol (80:20).
Human and Rat Plasma Samples after Multiple Oral Doses. Residual human plasma samples collected over 24 h on day 15 after consecutive once-daily doses of 40 mg of P were pooled to obtain one representative pooled sample for seven drug-treated subjects and three placebo-treated subjects, separately. Residual rat plasma samples collected over 24 h at the end of the 3-month rat TK study were pooled for the control, middle-dose, and high-dose groups. Plasma samples collected at different time points within 24 h after dosing were pooled in a time-interval proportional fashion (Hamilton et al., 1981; Hop et al., 1998) , so that the pooled samples represented the mean concentration (or AUC) for the time period. Aliquots of the plasma samples were mixed with 4 volumes of MeCN to precipitate proteins. The solvent in the supernatants was evaporated under vacuum at 30°C by using a centrifugal vacuum evaporator. The dry residues of the plasma samples were reconstituted with 5:95 (v/v) MeCN/aqueous solvent (e.g., 26 mM ammonium formate, pH 4.0, buffer) for metabolite profiling and identification with LC-UV-MS. Aliquots of 50-l pooled plasma samples were mixed with 400 l of acetonitrile containing 0.1 M 4-hydroxydiclofenac as an internal standard for LC-MS/MS quantitative analysis.
LC-MS. Table 1 summarizes LC-MS conditions for metabolite profiling or quantitative analysis. Aliquots of 50 l of reconstituted samples (including hepatocyte incubates, rat in vivo samples, human MAD study samples, and animal TK study samples) were injected for metabolite profiling and identification. For the hepatocyte incubates with [
14 C]P, data-dependent acquisition of collision-induced dissociation (CID) product-ion spectra were triggered by matching of the 12 C/ 14 C isotope pattern with that of the parent drug used in the incubations, e.g., M/(M ϩ 2.003) ion intensity ratio ϭ 1:0.95 (Ϯ0.07), as set in the present study. High-resolution MS scans were used for all samples. Ion-trap CID LC-MS/MS spectra were acquired for all metabolites detected in all samples. MS 3 CID spectra were acquired for metabolites in rat bile and urine.
Aliquots of 5 l of the supernatants of quenched incubation mixtures (including human liver microsomes, cytosol, and S9 fractions and human cDNA-expressed P450 and FMO enzymes) were injected for LC-MS/MS quantitative analysis. Calibration solutions of authentic standards were prepared in corresponding blank matrices by using authentic standard. In addition to the analysis of M1 and M2 in negative-ion mode (Table 1) , the parent drug P was quantified separately by using the ion transition of m/z 488.13348.1 in positive-ion mode. Quantitative analysis of M1 and M2 in pooled human MAD and TK plasma samples was performed similarly.
Radioactivity Monitoring. For [ 14 C]P metabolite profiling, approximately 90% of the LC eluate after the UV cell was split into either a radioflow detector or a fraction collector for off-line counting. Summarized information is presented in Table 1 . Radiochromatographic data were processed by using Laura 3 software (LabLogic Systems, Sheffield, UK). Microsoft Excel (Microsoft, Redmond, WA) was used to construct the radiochromatograms from TopCount (PerkinElmer Life and Analytical Sciences, Waltham, MA)-acquired raw data for LC fractions of rat in vivo samples; however, peak integration was performed by using Laura 3 software and inputting TopCount-acquired raw data into Laura 3 in LSC format.
Results
Figure 2 shows radiochromatographic profiles of metabolites found in human, rat, and dog hepatocyte incubates after incubation with 10 M [ 14 C]P. A total of six metabolites were observed in human or animal hepatocyte incubates, formed through either opening of the 1,2,4-oxadiazole ring (M1, M2, and M3) or oxidation of the piperazine group (M4, M5, and M6) (Scheme 4). The two metabolites observed in human hepatocytes (M1 and M2) were also found in rat and dog hepatocyte incubates (Fig. 2) . Phase II conjugate metabolites were not observed. The proposed metabolites in Scheme 4 were identified on the basis of the collective evidence from 1) the same (Table 2) were useful for structural elucidation of the mono-oxidation metabolites M4 and M5 and the unusual ring-opened metabolite M1. It was determined that mono-oxidation of M4 occurred on a heteroatom and not on a carbon, because the number of exchangeable hydrogen atoms in M4 remained unchanged from that in P (Table 2) . However, it has not been determined whether M4 is an N-oxide or an N-hydroxyl metabolite (Scheme 4). The H/D exchange results for the four-electron oxidation product M5 suggested two possibilities for its structure, i.e., no exchangeable proton (even after H/D exchange in D 2 O for 24 h before the LC-MS analysis) or no need for an ionizing proton (e.g., with an iminium group carrying a fixed positive charge). Na ϩ adduct ions of both 14 C-labeled and unlabeled M5 were observed in LC-MS scans and verified with accurate masses, which suggested that M5 might not have a fixed positive charge. Therefore, the M5 structure is proposed to contain imine and N-oxide groups (Scheme 4). H/D experimental results for metabolite M1 were consistent with the N-cyanoamide having an exchangeable -NH hydrogen but do not support an alternative chemical structure such as an intact 1,2,4-oxadiazole ring with a hydrogen at the 3-position, because that hydrogen would not be exchangeable. Eventually, the identity of the N-cyanoamide M1 and the carboxylic acid M2 were confirmed through LC-MS/MS comparison with authentic standards. Although the unusual N-cyanoamide metabolite M1 of compound P was observed as the major metabolite in human hepatocytes (Fig. 2a) , only trace amounts (0.1%) of M1 were found in either human liver microsomes or cytosol incubated in the presence of various cofactors. NADPH-dependent formation of M1 was observed in the human liver S9 fraction, with ϳ3.5% turnover from 10 M substrate. Depletion of the parent drug was noticed in human liver microsomal incubates of P in the presence of NADPH; however, only oxidations at the piperazine group were detected (e.g., M4 and a piperazine-hydroxylated metabolite) through LC-MS and MS/MS metabolite identification. On the basis of the absence of M1 from human liver microsomal incubates, it was not surprising that M1 was not produced at a level above noise or negative control levels by expressed human P450 enzymes or FMO enzymes (including CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, FMO1, FMO3, and FMO5). FMO1 and FMO3 metabolized P but produced only monooxidation metabolites at the piperazine group, as detected with LC-MS and MS/MS metabolite identification of the FMO incubates. The carboxylic acid metabolite M2 was also monitored in the in vitro incubates of human liver microsomes, cytosol, and S9 fractions and cDNA-expressed P450 and FMO enzymes. M2 was not detected in any of these in vitro incubations except with hepatocytes. In addition, incubation of synthetic M1 standard with human S9 fractions did not produce detectable M2.
The P450 enzyme inhibitor ABT and the FMO inhibitor methimazole did not abolish the NADPH-dependent formation of M1 in the human liver S9 fraction. Use of ABT in human or rat hepatocyte incubations also did not inhibit the formation of M1 or M2 in hepatocytes, where the turnover of M1 in the absence of the inhibitor was much higher than in the human S9 fraction. In the same experiment, ABT inhibited the metabolism of the CYP3A4 substrate midazolam, with more than 90% of the formation of 1Ј-hydroxylmidazolam metabolite being inhibited by ABT in both human and rat hepatocytes. observed between rat plasma in vivo and hepatocytes in vitro (Fig. 3 versus Fig. 2b ). After oral administration of 25 mg/kg [ 14 C]P to bile duct-cannulated (BDC) rats, urinary excretion accounted for mean recoveries of 6.1% and 13% of administered radioactivity for male and female rats, respectively. Excretion of the administered radioactivity in feces was 56% for both male and female BDC rats. Biliary elimination accounted for 34% and 24% of the dosed radioactivity for male and female rats, respectively.
The vast majority of administered [ 14 C]P radioactivity was excreted in the form of metabolites. The total of unchanged [
14 C]P in the bile, urine, and feces of BDC rats represented only ϳ1% of dosed radioactivity. Figure 4 shows radiochromatographic metabolite profiles for [
14 C]P in male rat bile, urine, and feces, acquired with pooled 0-to 48-h samples collected after oral dose administration to male BDC rats. Table 3 provides results for metabolites, as percentages of dosed radioactivity, excreted through the routes of bile, urine, and feces 0 to 48 h after oral administration of the dose of [
14 C]P to male or female BDC rats. The values in Table 3 were calculated on the basis of the percentages of metabolite peaks with respect to the total radioactivity peak area in radiochromatograms and radioactivity recovery through each elimination route.
The N-cyanoamide metabolite M1 accounted for most of the total radioactivity excreted in bile, urine, and feces of BDC rats, i.e., approximately 66 and 69% of the dose for male and female rats, respectively (Table 3 ). The carboxylic acid M2 was the next most abundant form of [
14 C]P-derived radioactivity excreted in bile, urine, and feces (ϳ7 and 6% of the dose for male and female rats, respectively) (Table 3) . A number of minor metabolites of [ 14 C]P were also observed in rat bile and urine (Fig. 4 , a and b; Scheme 5; Table 3 ); these included glucuronides M17a, M17b, and M17c (of the same aromatic carboxylic acid metabolite M2), rearranged Cys-piperazine adduct M13, oxadiazole ring-opened product M3, piperazine ringopened products (e.g., M10 and M11), and further oxidation products of the M1and M2 major metabolites (Scheme 5). In rat feces, the vast majority of [ 14 C]P-derived radioactivity was found to be the Ncyanoamide M1 ( Fig. 4c; Table 3 ), whereas unchanged P was not detected in the radiochromatogram (Fig. 4c) . Figure 5 shows the CID product-ion spectrum of [MϩH] ϩ ions of parent drug P. Most of the fragmentations of P occurred in the 1,2,4-oxadiazole and piperazine substructure regions (Fig. 5) . A fragment ion at m/z 348, produced through opening of the 1,2,4-oxazidazole ring (Fig. 5) , was also observed for all of the metabolites with an intact 5-Ar-oxadiazole substructure (spectra not shown here). A fragment ion at m/z 406 was not assigned because it would be difficult to rationalize (Fig. 5) . As indicated by accurate mass measurements, the m/z 406 ion had two additional hydrogen atoms, compared with the m/z 404 ion. The m/z 406 ion yielded fragment ions at m/z 365, 347, and 348 in MS 3 . The fragment ion at m/z 460 behaved almost like a reductive oxadizole ring-opened product of the m/z 404 ion, possibly formed through rearrangement involving the piperazine in the CID of compound P. Figure 6 compares the product-ion spectra of [MϩH] ϩ ions of the N-cyanoamide metabolite M1 and its authentic standard. The two spectra displayed perfect fingerprint-like matches (Fig. 6, a versus b) . In addition, identical retention times for the metabolite and the authentic standard were observed with two different LC methods, as described under Materials and Methods. The fragmentation of M1 differed dramatically from that of the parent compound P (Fig. 6 versus Fig. 5) ; instead, it appeared somewhat similar to that of the carboxylic acid M2 (spectra not shown here). Figure 7 provides the product-ion spectrum and spectral interpretation for M13, a rearranged Cys-piperazine adduct of compound P. The accurate mass measurements in LC-MS for M13 and the rearranged Gly-Cyspiperazine adduct M14 were within 1 ppm error of the theoretical exact masses, i.e., the same accuracy as for parent P and other metabolites (data not shown here). The structures for M13 and M14 were proposed on the basis of similar adducts of a piperazine-containing compound, N-(1-(4-(tert-butylcarbamoyl)-4-cyclohexylpiperidin-1-yl)-3-(4-fluorophenyl)-1-oxopropan-2-yl)-4-methylpiperazine-2-carboxamide (MB243), that was characterized previously with 1 H-NMR by Doss et al. (2005) . The metabolism involved ring contraction from a saturated six-membered piper- azine ring to an unsaturated five-membered ring derivative (Doss et al., 2005) . However, M13 and M14 contain a heteroaromatic imidazole (Scheme 5), instead of the imidazoline in the adducts of MB243 (Doss et al., 2005) . The product-ion spectrum of M13 showed some fragmentation patterns similar to findings reported for the rearranged Cys adduct of MB243 (Doss et al., 2005) , e.g., the characteristic neutral loss of 131, which produced a fragment ion at m/z 470 from the [MϩH] ϩ ion for M13 (Fig. 7) . In addition, fragmentation through neutral loss of CO 2 and loss of H 2 O plus CO, which yielded fragment ions at m/z 557 and 555, respectively, indicated a carboxylic group in M13 (Fig. 7) . As indicated in Fig. 7 , most of the abundant fragment ions for M13 corroborated the proposed structure.
M17a, M17b, and M17c in rat bile (Fig. 4a) were identified as migrated acyl glucuronides of the aromatic carboxylic acid M2. Metabolites M17a, M17b, and M17c had identical accurate masses and produced the same fragment ions through CID. The intensity ratios of fragment ions of M17a, M17b, and M17c were distinct from one another (spectra not shown here), which is typical for isomeric compounds.
M12 and M18, two minor metabolites found in rat bile, were proposed to have formamide structures (Scheme 5). As an example of experimental evidence supporting the proposed structures, the further fragmentation in LC-MS 3 for M12, after neutral CO loss from the [MϩH] ϩ ions of M12, yielded a MS 3 spectrum that was identical to the M10 MS/MS spectrum (spectra not shown here). These formamide metabolites were shown not to be artifacts of chemical transformation of corresponding secondary amines by formic acid in the LC mobile phase, because M12 and M18 were also detected in LC-MS experiments using acetic acid or ammonium acetate buffer as the mobile phase. Figure 8a overlays UV chromatograms of pooled human plasma samples collected over 24 h on day 15 after consecutive once-daily doses of 40 mg of P versus placebo. The parent drug P reached the steady state after approximately 10 days (pharmacokinetic data not shown here). Figure 8b provides a LC-MS accurate mass extract ion chromatogram showing M1, M2, and M3 metabolite peaks in the plasma sample. It is evident from the overlaid UV chromatogram (Fig.  8a ) that M1 and M2 are major metabolites in the human plasma sample, with exposure levels much higher than those of the parent P, whereas M3 is a minor metabolite. The identities of the major human metabolites N-cyanoamide M1 and carboxylic acid M2 were confirmed in LC-MS/MS analyses with their authentic standards, with both LC methods described under Materials and Methods. The 0-to 24-h mean concentrations of M1 and M2 as determined in the pooled day 15 plasma sample through LC-MS/MS quantitative analysis were 4.6 and 7.9 M, respectively, whereas the mean concentration of SCHEME 5. Proposed biotransformation scheme for [
14 C]P in rats.
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unchanged P was only 0.24 M. Therefore, the exposure of M1 and M2 in humans was 19 and 33 times higher, respectively, than that of P on a molar basis. It worth noting that neither M1 nor M2 showed any target activity as did the parent drug P, as determined in an in vitro bioassay. All three human plasma metabolites (M1, M2, and M3) were detected in rat plasma from the radiolabeled study (Fig. 3) . Exposure coverage for the major human metabolites M1 and M2 in a rat oral TK study was determined first through qualitative metabolite analysis of both pooled MAD human plasma and 3-month TK animal plasma samples by using LC-UV-MS (data not shown), and results were confirmed quantitatively through LC-MS/MS bioanalysis of the human and rat plasma samples. The pooling method adopted in the present study yielded pooled samples in which the concentration of any analyte was directly proportional to its AUC (more specifically, the mean concentration across the pooled time range) Hop et al., 1998) . The bioanalytical results for M1 and M2 in pooled human plasma and rat TK plasma samples are provided in Table 4 . The rat TK study overall had greater exposure to M1 and M2 than did the human study, and the middle rat dose of 15 mg/kg, with which there were no observable adverse effects, gave greater exposure to M2 than in the human study (Table 4 ). The results in Table 4 indicate the toxicological coverage of the major human metabolites M1 and M2 in at least one preclinical species.
Discussion
The unusual N-cyanoamide metabolite (M1) would have been missed without the use of radiolabeled material, such as in the drug discovery process. The existence of the strongly retained M1 was discovered when low levels of radioactivity recovery from the LC column were observed in early [
14 C]P metabolite profiling of in vitro incubates. It was intriguing how simple solution-based chemistry affected the LC elution of M1. Currently, formic acid or TFA is often the top choice for mobile-phase modifier in many LC-MS laboratories, because of the generally greater ionization efficiency in positiveion electrospray at low pH, the unstable nature of some organic buffers because of microorganism contamination, or simply the inconvenience of preparing organic buffers. However, when formic acid or TFA was used in the mobile phase with a C18 column, M1 was so strongly retained that it did not elute from the column without being washed with 100% organic mobile phase at the end of the LC gradient. The LC column used for the present study is a C18-type column but with polar end-cap groups that may allow the elution of M1. The elution orders of M1 and M2 versus P were noticeably affected by the pH of the mobile phases. Both M1 and M2 eluted after P with 0.05% formic acid aqueous mobile phase (pH Ͻ 2) (Figs. 2 and  3) . With pH 4.0 formate buffer, M1 eluted before P (Fig. 4) . When pH 5.0 acetate buffer was used, both M1 and M2 eluted ahead of P (chromatograms not shown). Compound P should be positively charged at the piperazine under all of these pH conditions. Observations on the earlier elution of M1 at higher pH values are consistent with the N-cyanoamide being an organic acid, because the -NH can be deprotonated to yield a negative charge that is stabilized by both the carbonyl and cyano groups. With low-pH mobile phases, however, such as 0.05% formic acid, the N-cyanoamide group is neutral; therefore, with the lipophilic Ar group, the M1 molecule would be highly lipophilic and strongly retained on the HPLC column.
Possibly both cytosolic and membrane-bound enzymes contributed to M1 formation, because M1 was produced in human hepatocytes and human liver S9 fractions in the presence of NADPH but was not generated by either human liver microsomes or human liver cytosol alone. ABT did not inhibit the formation of M1 in hepatocytes and the S9 fraction, which suggests that cytochrome P450 enzymes probably are not involved or are not involved to a significant extent. M2 is thought to be formed through reductive N-O cleavage and subsequent hydrolysis (Lan et al., 1973; Allan et al., 2006) . The absence of M2 from human liver S9 fraction incubates of the M1 authentic standard suggests that the carboxylic acid metabolite M2 may not be formed through hydrolysis of the N-cyanoamide metabolite M1.
Doss and colleagues discovered unusual rearranged Cys-piperazine and Gly-Cys-piperazine adducts, after noticing that high levels of FIG. 5 . LC-MS/MS product-ion spectrum acquired for [MϩH] ϩ ions of the parent drug P.
covalent binding of the piperazine-containing melanocortin subtype 4 receptor agonist MB243 in rat and human liver microsomes were attenuated by GSH (Doss et al., 2005; Doss and Baillie, 2006) . On the basis of their NMR structural characterization of isolated metabolites from rat bile, Doss et al. (2005) proposed a mechanism for bioactivation of the piperazine ring that led to ring contraction to afford an imidazoline derivative. Their mechanism has been adapted in Scheme 6 to rationalize the formation of the Cys adduct M13 and the Gly-Cys adduct M14 seen in rat bile. However, an additional dehydrogenation step occurred in the metabolism of compound P, which led to the aromatization and formation of an imidazole ring (Scheme 6) instead of an imidazoline as for MB243. This difference could possibly be attributable to steric hindrance of a bulky substituent group at a piperazine carbon ring in MB243 (Doss et al., 2005; Doss and Baillie, 2006) , which might have prevented the dehydrogenation step from occurring. The absence of a dihydro intermediate from metabolic aromatization such as the formation of M13 and M14 is not new in the literature, because two articles previously described the absence of dihydro intermediates from the formation of N-alkylquinolinium metabolites (Shaffer et al., 2001; Gu et al., 2006) . In summary, it seems that the metabolic pathway leading to a rearranged Cys-piperazine adduct originally discovered by Doss et al. (2005) is a common GSH detoxification mechanism for piperazine bioactivation products. Two formamide metabolites, M12 and M18, were observed as minor metabolites in rat bile (Scheme 4). We proved that these formamides were not artifacts in the LC-MS metabolite profiling process. However, it is unclear how the formamide metabolites M12 and M18 were formed in rats. Shaffer et al. (2009 Shaffer et al. ( , 2010 ) also reported FIG. 6 . LC-MS/MS product-ion spectra acquired for [MϩH] ϩ ions of metabolite M1 (a) and authentic standard compound 1 (b).
FIG. 7. LC-MS/MS product-ion spectrum acquired for [MϩH]
ϩ ions of the rearranged Cys-piperazine adduct metabolite M13. Metabolite analysis to rationalize the safety of drug metabolites according to Food and Drug Administration guidance can involve two analytical issues, i.e., detection of metabolites in complex biological matrices such as human plasma at steady state without reliance on radiolabels, because the most readily available human plasma samples at steady state would be derived from multiple-dose studies with unlabeled drug, and determination of which circulating metabolites in humans are significant enough for quantitative or semiquantitative comparison of humans versus preclinical species. Computer algorithms for background subtraction from LC/high-resolution MS data have been demonstrated to be effective approaches to reveal drug metabolites in complex biological matrices (Zhang et al., 2008b; Zhang and Yang, 2008; Zhu et al., 2009 ). Unlike radioactivity monitoring of metabolites for which the physical properties of the radioactive nucleus (e.g., 14 C) are not affected by biotransformation at the molecular level, the LC-MS signal-response efficiency of metabolites varies, sometimes dramatically, such as with the acidic metabolites M1 and M2 of the basic parent compound P in the present study. The present study has provided an example that, under certain circumstances, traditional UV detection can help to identify major plasma metabolites, when the parent drug and metabolites exhibit reasonably strong UV absorption and the concentrations in plasma are not too low (Fig. 8) . Because of the availability of authentic standards for both M1 and M2, quantitative comparison of the plasma metabolites was not a significant analytical issue after they were identified as the major metabolites in human plasma. If the standards had not been available, it would still have been possible to obtain quantitative estimates of exposure coverage, e.g., with the use of radiolabeled M1 and M2 metabolites in rat samples as references for correlation of MS signal responses for unlabeled metabolites in the pooled human MAD and animal TK plasma samples. However, that would be beyond the scope of this article.
